ClinicalTrials.Veeva

Menu
M

Mountain Neurological Research Center | Basalt, CO

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Simufilam
Tolebrutinib
Donanemab
Erenumab
Tyrosine
Remternetug
SAR442168
Semagludtide
Ocrelizumab
LY3372993

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 14 total trials

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer´s Disease
Drug: Placebo (semaglutide)
Drug: Semaglutide

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer's Disease
Drug: Placebo (semaglutide)
Drug: Semagludtide

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Enrolling
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic A...

Active, not recruiting
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizuma...

Begins enrollment this month
Relapsing-remitting Multiple Sclerosis (RRMS)
Drug: Ocrelizumab (EU)
Drug: Ocrelizumab (US)

The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RET...

Active, not recruiting
Alzheimer Disease
Drug: Simufilam

Trial sponsors

Lilly logo
Amgen logo
C
Novo Nordisk logo
Sanofi logo
Biogen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems